LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Developed to Detect Breast Cancer

By LabMedica International staff writers
Posted on 12 May 2014
Image: The Octava blood tests, developed for rapid, accurate detection of breast cancer tumors (Photo courtesy of Eventus Diagnostics).
Image: The Octava blood tests, developed for rapid, accurate detection of breast cancer tumors (Photo courtesy of Eventus Diagnostics).
A simple blood test has been developed as an easy, noninvasive method to detect breast cancer and is designed to be used in conjunction with annual screening mammograms.

The developed assay has been described as an accurate, cost-effective, immune system-based means of detection by measuring breast cancer-specific autoantibodies to detect the presence or absence of breast cancer.

The blood test has been validated by clinical studies conducted at cancer centers in the USA, Israel, and Italy that analyzed blood samples from over 800 women. The women in the trial all had positive mammograms and their breast cancer pathologies were verified by biopsy. The test measures cancer-specific antibodies produced by the immune system in response to the growth of tumors, and can be used both to quickly diagnose breast cancer before tumors become visible in mammogram, as well as identify false negative and false positive mammogram results.

The Octava tests were developed by Eventus Diagnostics’ subsidiary (Moshav Ora, Israel) and the two chip-based tests, called Octava Pink and Octava Blue, require the patient to donate a small sample of plasma to quickly determine the presence of the antibodies. The Octava Blue test is designed for use in conjunction with screening mammograms to provide additional diagnostic information to help physicians confirm true abnormal mammography results with high accuracy, while also helping to reduce the large number of unnecessary biopsies caused by false positive results.

The Octava Pink test is designed to provide additional diagnostic information to help physicians confirm true negative mammography findings with high accuracy, while helping to identify the presence of cancer in more than half of the cases where mammography produces a false negative result and cancer is actually present. The Octava Pink test can also provide additional information to address the estimated 5% of core needle breast biopsy results that represent false negative findings. The information from Octava Pink could help physicians detect at least half of those cases where cancer is actually present, possibly triggering an additional biopsy. Octava Pink may also be useful to physicians caring for women who will not or cannot receive mammograms.

Marvin M. Rosenberg, DDS, the president of Eventus Diagnostics, said, “The tests could be used by women with dense breast tissue who received normal mammogram results, or by women hoping to detect tumor cells without exposing themselves to radiation. Over 30% of breast cancer cases in women with dense breast tissue are missed by mammograms, a gap Eventus’ technology aims to address.” Eventus recently secured USD 2.72 million in funding to finance a large clinical study of the Octava tests to support its application for US Food and Drug Administration (FDA; Silver Spring, MD, USA) clearance.

Related Links:

Eventus Diagnostics
US Food and Drug Administration


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
PlGF Test
Quidel Triage PlGF Test

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL